All Comments by Benjamin Wolozin
- Presenting: A Not-Quite-Parkinson's Mouse Model
- Effects of environmental enrichment on gene expression in the brain.
- Presenilin-1 P264L knock-in mutation: differential effects on abeta production, amyloid deposition, and neuronal vulnerability.
- ASP1 (BACE2) cleaves the amyloid precursor protein at the beta-secretase site.
- Identification of ubiquilin, a novel presenilin interactor that increases presenilin protein accumulation.
- Domain homologues of dopamine beta-hydroxylase and ferric reductase: roles for iron metabolism in neurodegenerative disorders?
- The C-terminal fragment of the Alzheimer's disease amyloid protein precursor is degraded by a proteasome-dependent mechanism distinct from gamma-secretase.
- Estrogen lowers Alzheimer beta-amyloid generation by stimulating trans-Golgi network vesicle biogenesis.
- Interaction of human alpha-Synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis.
- Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain.
- Identification of genes that modify ataxin-1-induced neurodegeneration.
- Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains.
- Staging of neurofibrillary degeneration caused by human tau overexpression in a unique cellular model of human tauopathy.
- p35/cdk5 binds and phosphorylates beta-catenin and regulates beta-catenin/presenilin-1 interaction.
- Biochemical identification of the neutral endopeptidase family member responsible for the catabolism of amyloid beta peptide in the brain.